Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Approval Positions Roxadustat As Japan HIF-PHI Leader

Wed, 09/25/2019 - 7:14pm

The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH...

      Related Stories 

Last Two Of Three Big Inclisiran Studies Boosts The Medicines Co.

Wed, 09/25/2019 - 3:54pm

Filings for the twice-yearly anti-PCSK9 injection under a partnership with Alnylam are on track, including a fourth quarter submission in...

      Related Stories 

Urogen's Novel Formula For Urothelial Cancer Presents Unique Commercial Challenges

Wed, 09/25/2019 - 1:28pm

The company expects to launch a proprietary gel formulation of chemo drug mitomycin for urothelial cancer in the first half...

      Related Stories 

Deep Genomics' AI Platform Helped Discover New Wilson Disease Drug Candidate

Wed, 09/25/2019 - 12:41pm

The startup's artificial intelligence-based platform helped the company identify its first drug candidate in one-fifth the usual timespan, CEO Brendan...

      Related Stories 

Interview: Amryt Aims High After Aegerion Acquisition

Wed, 09/25/2019 - 8:08am

The Irish firm's CEO told Scrip about a transformative deal for Amryt, creating an international business with revenues of nearly...

      Related Stories 

Monkeypox Vaccine Approval A Shot In The Arm For Bavarian

Wed, 09/25/2019 - 8:08am

Nigeria's monkeypox outbreak represents opportunity for Danish company still looking to overcome cancer vaccine setback.

      Related Stories 

Helixmith Facing Engensis Challenges After Disappointing First Phase III Data

Tue, 09/24/2019 - 11:11pm

Helixmith delays making conclusions on disappointing first top-line data from lead US Phase III study of plasmid DNA therapeutic Engensis...

      Related Stories 

Glenmark Has An Orphan Ahead of Innovation Capital Raising Plan

Tue, 09/24/2019 - 5:50pm

FDA orphan drug designation for Glenmark’s multiple myeloma candidate is seen as an important milestone ahead of its innovation spin...

      Related Stories 

Omega Therapeutics Looks To Address Disease By Tuning Genomic Regulators

Tue, 09/24/2019 - 1:09pm

The newest Flagship spinout says that by drugging insulated genomic domains, it can tune genomic activity without altering DNA to...

      Related Stories 

Sandoz Recalls Antacid In Another Generics Firestorm

Tue, 09/24/2019 - 1:05pm

The Novartis unit moved to recall all lots of ranitidine capsules in the US due to confirmed contamination with NDMA.

      Related Stories 

Interview: The Pace Quickens For Calliditas's Berger's Disease Candidate

Tue, 09/24/2019 - 7:49am

A Phase III trial design change could result in quicker patient access for Calliditas’s product candidate for Berger’s disease, and...

      Related Stories 

Pages